Minimal Blood Pressure Effects of Intranasal Etripamil for Paroxysmal Supraventricular Tachycardia
James E. Ip, Peter Noseworthy, Farhad Rafii, Jonathan P. Piccini, Narendra Singh, Bruce Stambler, Silvia Shardonofsky, David B. Bharucha, A. John Camm · 2026
Read Minimal Blood Pressure Effects of Intranasal Etripamil for Paroxysmal Supraventricular Tachycardia by James E. Ip, Peter Noseworthy, Farhad Rafii, Jonathan P. Piccini, Narendra Singh, Bruce Stambler, Silvia Shardonofsky, David B. Bharucha, A. John Camm (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/PMC13267542.txt.
Description
James E Ip and colleagues report a 2026 analysis of blood pressure effects of a nose-spray heart drug. Etripamil is a self-given spray for sudden fast heart rhythms, the first of its kind approved in the United States. Other calcium channel blockers, given by vein or mouth, can drop blood pressure or cause fainting. The team asked whether the spray does the same.
The analysis pooled over 1,600 people treated across the drug's phase 3 trials from 2018 to 2023. Low blood pressure occurred in only about 0.4 percent of participants, and fainting in about 0.2 percent. Test doses given while the heart beat normally let the team watch pressure closely. The authors conclude the spray has minimal effects on blood pressure.
Catalog record
| CREATOR | James E. Ip, Peter Noseworthy, Farhad Rafii, Jonathan P. Piccini, Narendra Singh, Bruce Stambler, Silvia Shardonofsky, David B. Bharucha, A. John Camm |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 10707 |
| LICENSE | https://creativecommons.org/licenses/by/4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |